Daily Respiratory Research Analysis
Three impactful studies span prevention, health services, and surgery in respiratory medicine: a mechanistic study shows that lowering defective interfering particles in live attenuated influenza vaccines markedly enhances mucosal immunity and cross-protection in mice; a UK real-world economic evaluation finds comprehensive post-hospital COVID-19 services are clinically effective and highly cost-effective; and a meta-analysis indicates sublobar resection offers comparable survival to lobectomy i
Summary
Three impactful studies span prevention, health services, and surgery in respiratory medicine: a mechanistic study shows that lowering defective interfering particles in live attenuated influenza vaccines markedly enhances mucosal immunity and cross-protection in mice; a UK real-world economic evaluation finds comprehensive post-hospital COVID-19 services are clinically effective and highly cost-effective; and a meta-analysis indicates sublobar resection offers comparable survival to lobectomy in stage Ia NSCLC, with higher local recurrence unless systematic nodal sampling is performed.
Research Themes
- Optimizing live attenuated influenza vaccines by controlling defective interfering particles (DIPs)
- Cost-effective models of comprehensive post-hospital care for long COVID
- Surgical decision-making in early-stage NSCLC: sublobar resection versus lobectomy
Selected Articles
1. Live attenuated influenza vaccine with low proportions of defective interfering particles elicits robust immunogenicity and cross-protection.
Reducing defective interfering particles in an H3N2 LAIV enhanced mucosal and humoral immunity, increased antigen-presenting and mucosal cell subsets, and conferred complete cross-protection against multiple influenza A strains in mice. These data suggest controlling DIPs may be a generalizable lever to improve the efficacy of LAIVs and related replicative RNA virus vaccines.
Impact: This work identifies a practical, mechanistically grounded manufacturing parameter—DIP proportion—that substantially boosts LAIV immunogenicity and breadth in vivo, with immediate translational implications for vaccine optimization.
Clinical Implications: If validated in humans, LAIV production strategies that minimize DIPs could yield vaccines with stronger mucosal immunity and broader cross-strain protection, potentially improving seasonal effectiveness and pandemic preparedness.
Key Findings
- Low-DIP H3N2 LAIV showed delayed yet improved upper respiratory tract replication in mice versus high-DIP LAIV.
- Enhanced mucosal (e.g., goblet and microfold cells) and innate/adaptive immune features (increased antigen presentation by dendritic cells).
- Stronger mucosal and humoral responses and cross-neutralization compared with commercial high-DIP LAIV.
- Complete protection against lethal H3N2, H1N1, and H1N1pdm09 challenges.
Methodological Strengths
- Direct head-to-head comparison of low-DIP versus high-DIP LAIV formulations with in vivo functional readouts.
- Comprehensive immune phenotyping and multi-strain lethal challenge model demonstrating breadth of protection.
Limitations
- Preclinical murine data; human immunogenicity, safety, and effectiveness remain untested.
- Operational measurement/control of DIP proportions at manufacturing scale and across strains needs validation.
Future Directions: Translate to human LAIV manufacturing with standardized DIP quantification, followed by phase 1–2 clinical trials assessing mucosal immunity, breadth, and effectiveness.
Commercial live attenuated influenza vaccines (LAIVs) usually contain a high proportion of defective interfering particles (DIPs). Given that LAIVs are not sufficiently protective worldwide, the potential to enhance their efficacy by reducing the proportion of DIPs remains largely unknown. In this study, a prepared H3N2 cold-adapted LAIV with a low proportion of DIPs exhibits delayed yet improved replication in the upper respiratory tract of mice. The low DIPs LAIV induces an increase in goblet cells, microfold cells, and neutrophils, along with enhanced antigen presentation by dendritic cells. Compared to the commercially sourced high DIPs LAIV, the low DIPs LAIV elicits enhanced mucosal and humoral immune responses, facilitates cross-neutralization in mice, and provides complete protection against lethal challenges with H3N2, H1N1 or H1N1pdm09 strains. This study offers insights into optimizing commercial LAIVs and replicative RNA virus-based vaccines by controlling DIPs.
2. Clinical and cost-effectiveness of diverse posthospitalisation pathways for COVID-19: a UK evaluation using the PHOSP-COVID cohort.
In a prospective UK cohort of 1,013 post-hospital COVID-19 patients followed for 12 months, comprehensive services (assessment, rehabilitation, and mental health) yielded higher QALYs than no or ‘light touch’ services at a low incremental cost (~£1700 per QALY). Only 29% reported feeling fully recovered, and 41% had newly diagnosed conditions, underscoring ongoing needs.
Impact: Provides policy-relevant evidence that comprehensive, stratified post-hospital pathways for long COVID are both clinically beneficial and highly cost-effective.
Clinical Implications: Health systems should prioritize proactive assessment, rehabilitation, and mental health support after COVID-19 hospitalization; these services likely deliver QALY gains at favorable cost-effectiveness thresholds.
Key Findings
- At 12 months, only 29% reported full recovery; 41% had newly diagnosed conditions.
- Comprehensive services improved QALYs versus no or light-touch services (0.789 vs 0.725).
- Estimated incremental cost-effectiveness was ~£1700 per QALY, within or below commonly accepted thresholds.
Methodological Strengths
- Prospective, multicenter real-world cohort with 12-month follow-up and linked resource-use data.
- Cost-utility analysis using EQ-5D-5L-derived QALYs with statistical adjustment for observed confounding.
Limitations
- Observational design with potential residual confounding despite adjustment.
- Findings reflect UK post-hospitalized population; generalizability to non-hospitalized long COVID and other health systems may be limited.
Future Directions: Evaluate long-term (≥24 months) outcomes, refine stratification to target high-yield components, and test implementation models across diverse health systems.
BACKGROUND: Long covid has emerged as a complex health condition for millions of people worldwide following the COVID-19 pandemic. Previously, we have categorised healthcare pathways for patients after discharge from hospital with COVID-19 across 45 UK sites. The aim of this work was to estimate the clinical and cost-effectiveness of these pathways. METHODS: We examined prospectively collected data from 1013 patients at 12 months postdischarge on whether they felt fully recovered (self-report), number of newly diagnosed conditions (NDC), quality of life (EuroQoL-five dimension-five level (EQ-5D-5L) utility score compared with pre-COVID estimate) and healthcare resource costs (healthcare records). An analysis of the cost-effectiveness was performed by combining the healthcare resource cost and 1-year EQ-5D (giving a quality-adjusted life-year (QALY)) using statistical models that accounted for observed confounding. RESULTS: At 1 year, 29% of participants felt fully recovered, and 41% of patients had an NDC. The most comprehensive services, where all patients could potentially access assessment, rehabilitation and mental health services, were more clinically effective when compared with either no service or light touch services (mean (SE) QALY 0.789 (0.012) vs 0.725 (0.026)), with an estimated cost per QALY of £1700 (95% uncertainty interval: dominated to £24 800). CONCLUSION: Our analysis supports the need for proactive, stratified, comprehensive follow-up, particularly assessment and rehabilitation for adults after hospitalisation with COVID-19, showing these services are likely to be both clinically and cost-effective according to commonly accepted thresholds.
3. Sublobar resection or lobectomy for stage Ia non-small cell lung cancer: a systematic review and meta-analysis.
Across 19 studies (4 RCTs), sublobar resection and lobectomy achieved comparable 5-year overall and disease-free survival for clinical stage Ia NSCLC (<2 cm). Sublobar resection had higher local recurrence overall, but when systematic hilar and mediastinal lymph node sampling was mandated, sublobar resection showed improved overall survival.
Impact: Synthesizes contemporary trial and observational data to refine surgical decision-making in early NSCLC, highlighting the pivotal role of systematic nodal staging when considering sublobar resection.
Clinical Implications: For tumors <2 cm (stage Ia), sublobar resection can be considered without compromising long-term survival, provided systematic hilar and mediastinal nodal sampling is performed; clinicians should discuss higher local recurrence risk and ensure thorough nodal staging.
Key Findings
- Five-year overall survival (HR 1.00) and disease-free survival (HR 1.05) were comparable between lobectomy and sublobar resection.
- Local recurrence was significantly higher with sublobar resection (OR 1.86; I²=73%).
- In studies mandating systematic hilar and mediastinal lymph node sampling, sublobar resection showed improved overall survival (HR 0.81; I²=0%).
- No differences observed in 10-year survival or postoperative FEV1 change.
Methodological Strengths
- Inclusion of randomized trials and rigorous risk-of-bias assessment (RoB2 and ROBINS-I).
- Random-effects meta-analyses with subgroup exploration of nodal sampling mandates.
Limitations
- Substantial heterogeneity for local recurrence and long-term endpoints (high I²), reflecting variations in technique and selection.
- Mix of RCTs and observational studies may introduce residual confounding and protocol variability (e.g., extent of nodal sampling).
Future Directions: Standardize nodal assessment during sublobar resection and conduct patient-level meta-analyses to clarify recurrence drivers; evaluate functional and quality-of-life trade-offs prospectively.
BACKGROUND: This systematic review and meta-analysis synthesises evidence from both randomised trials and observational studies to determine whether lobectomy or sublobar resection offers improved outcomes for patients with stage Ia non-small cell lung cancer (NSCLC). METHODS: Studies (up to June 2025) comparing lobectomy and sublobar resection (segmentectomy or wedge) for clinical stage Ia NSCLC (<2 cm) were included in the random-effects meta-analyses. Risk of bias was assessed using Risk of Bias 2 for randomised trials or Risk of Bias in Non-randomised Studies of Interventions-I for observational studies. RESULTS: 19 studies, including four randomised trials, were included. Overall survival at 5 years was comparable between lobectomy and sublobar resection (HR=1.00; 95% CI 0.84 to 1.19; I²=26%), as was disease-free survival (HR=1.05; 95% CI 0.90 to 1.23; I²=0%). Sublobar resection was associated with significantly higher local recurrence (OR=1.86; 95% CI 1.07 to 3.25; I²=73%). No differences were observed in 10-year survival (OR=0.99; 95% CI 0.27 to 3.59; I²=86%) or postoperative change in forced expiratory volume in 1 s (mean difference=-4.70; 95% CI -11.15 to 1.76; I²=99%). In 10 studies that mandated systematic hilar and mediastinal lymph node sampling, sublobar resection was associated with improved overall survival compared with lobectomy (HR=0.81; 95% CI 0.69 to 0.965; I²=0%). CONCLUSION: Lobectomy and sublobar resection offer comparable long-term survival for patients with stage Ia NSCLC. While sublobar resection is associated with higher local recurrence rates, subgroup analysis suggests that when intraoperative systematic hilar and mediastinal lymph node sampling is performed, sublobar resection may offer a survival advantage.